Osteosarcoma is the most common primary malignant tumour of the bone. Osteosarcoma
incidence is bimodal, peaking at 18 and 60 years of age, and is slightly more common in …

Over the past decade, CRISPR has become as much a verb as it is an acronym,
transforming biomedical research and providing entirely new approaches for dissecting all …

The majority of oncogenic drivers are intracellular proteins, thus constraining their
immunotherapeutic targeting to mutated peptides (neoantigens) presented by individual …

Ferroptosis has emerged as an attractive strategy in cancer therapy. Understanding the
operational networks regulating ferroptosis may unravel vulnerabilities that could be …

The majority of oncogenic drivers are intracellular proteins, constraining their
immunotherapeutic targeting to mutated peptides (neoantigens) presented by individual …

A lack of relevant genetic models and cell lines hampers our understanding of
hepatoblastoma pathogenesis and the development of new therapies for this neoplasm …

Fusion-transcription factors (fusion-TFs) represent a class of driver oncoproteins that are
difficult to therapeutically target. Recently, protein degradation has emerged as a strategy to …

Pediatric solid and central nervous system tumors are the leading cause of cancer-related
death among children. Identifying new targeted therapies necessitates the use of pediatric …

Transcription factors (TFs) are frequently mutated in cancer. Paediatric cancers exhibit few
mutations genome-wide but frequently harbour sentinel mutations that affect TFs, which …

Genetic screens in cancer cell lines inform gene function and drug discovery. More
comprehensive screen datasets with multi-omics data are needed to enhance opportunities …